Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$39.98

0.3 (0.76%)

, MRK

Merck

$83.30

0.52 (0.63%)

06:16
06/18/19
06/18
06:16
06/18/19
06:16

AstraZeneca's Lynparza approved as 1st line ovarian cancer maintenance treatment

AstraZeneca (AZN) and Merck (MRK) announced that the European Commission has approved Lynparza as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response following completion of 1st-line platinum-based chemotherapy. Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "This approval sets the stage for a new standard of care in the EU for women with ovarian cancer and a BRCA mutation. The goals of front-line therapy have always been long-term remission and even cure, yet currently 70% of patients relapse within three years of initial treatment. The progression-free survival benefit of Lynparza observed in SOLO-1 represents a major step forward in our ambition to help transform patient outcomes." The EC approval was based on data from the pivotal Phase III SOLO-1 trial which tested Lynparza as maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer following 1st-line platinum-based chemotherapy. Results announced in October 2018 at 40.7 months of follow-up showed the median time of progression for patients treated with Lynparza had not yet been reached vs. 13.8 months for those on placebo. This is the third indication for Lynparza in the EU. AstraZeneca and MSD are exploring additional trials in ovarian cancer, including the ongoing Phase III PAOLA-1 trial, which is testing Lynparza in combination with bevacizumab as a 1st-line maintenance treatment for women with newly-diagnosed, advanced, stage IIIB-IV high grade serous or endometrioid ovarian cancer, regardless of BRCA status.

AZN

AstraZeneca

$39.98

0.3 (0.76%)

MRK

Merck

$83.30

0.52 (0.63%)

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 24

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 16

    Sep

  • 20

    Sep

AZN AstraZeneca
$39.98

0.3 (0.76%)

05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
MRK Merck
$83.30

0.52 (0.63%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
07/15/19
07/15
15:17
07/15/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
07/15/19
07/15
15:16
07/15/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

$132.61

-0.12 (-0.09%)

15:14
07/15/19
07/15
15:14
07/15/19
15:14
Hot Stocks
Wabco moves lower in afternoon trading »

The move lower in shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUN

Cedar Fair

$50.50

0.4 (0.80%)

15:10
07/15/19
07/15
15:10
07/15/19
15:10
Conference/Events
Cedar Fair participates in a conference call with Wedbush »

Leisure & Travel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 07

    Aug

SCHW

Charles Schwab

$40.40

0.38 (0.95%)

15:06
07/15/19
07/15
15:06
07/15/19
15:06
Recommendations
Charles Schwab analyst commentary  »

Charles Schwab deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

FB

Facebook

$204.99

0.085 (0.04%)

, GOOG

Alphabet

$1,147.08

2.53 (0.22%)

15:04
07/15/19
07/15
15:04
07/15/19
15:04
Periodicals
Facebook hires former Vine chief to its new experimental app division, Verge say »

Chaim Gartenberg of the…

FB

Facebook

$204.99

0.085 (0.04%)

GOOG

Alphabet

$1,147.08

2.53 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

WTFC

Wintrust Financial

$70.39

-1.65 (-2.29%)

15:04
07/15/19
07/15
15:04
07/15/19
15:04
Options
Wintrust Financial options imply 4.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 06

    Aug

GLPG

Galapagos

$169.98

24.31 (16.69%)

, GILD

Gilead

$68.00

1.75 (2.64%)

14:56
07/15/19
07/15
14:56
07/15/19
14:56
Downgrade
Galapagos, Gilead rating change  »

Galapagos downgraded to…

GLPG

Galapagos

$169.98

24.31 (16.69%)

GILD

Gilead

$68.00

1.75 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 26

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

JPM

JPMorgan

$114.02

-1.3 (-1.13%)

, JNJ

Johnson & Johnson

$134.89

0.6 (0.45%)

14:53
07/15/19
07/15
14:53
07/15/19
14:53
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JPM

JPMorgan

$114.02

-1.3 (-1.13%)

JNJ

Johnson & Johnson

$134.89

0.6 (0.45%)

WFC

Wells Fargo

$46.66

-0.69 (-1.46%)

GS

Goldman Sachs

$211.67

-2.28 (-1.07%)

PLD

Prologis

$80.11

0.08 (0.10%)

FRC

First Republic

$98.89

-1.74 (-1.73%)

DPZ

Domino's Pizza

$269.81

-12.42 (-4.40%)

SNV

Synovus

$34.65

-0.78 (-2.20%)

FHN

First Horizon

$14.89

-0.22 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 29

    Jul

  • 30

    Jul

  • 06

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 12

    Oct

  • 13

    Nov

JBHT

J.B. Hunt

$92.62

-0.33 (-0.36%)

14:52
07/15/19
07/15
14:52
07/15/19
14:52
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

JBHT

J.B. Hunt

$92.62

-0.33 (-0.36%)

14:49
07/15/19
07/15
14:49
07/15/19
14:49
Options
J B Hunt Transport Services options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

AGRX

Agile Therapeutics

$1.30

0.01 (0.78%)

14:48
07/15/19
07/15
14:48
07/15/19
14:48
Recommendations
Agile Therapeutics analyst commentary at Oppenheimer »

FDA guidance looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$41.82

0.575 (1.39%)

14:45
07/15/19
07/15
14:45
07/15/19
14:45
Options
Taiwan Semi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ALTR

Altair

$41.54

0.37 (0.90%)

14:37
07/15/19
07/15
14:37
07/15/19
14:37
Hot Stocks
Altair beneficial owner George Christ sells $1.5M in company shares »

Altair beneficial owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$211.82

-2.13 (-1.00%)

, BAC

Bank of America

$29.19

-0.25 (-0.85%)

14:36
07/15/19
07/15
14:36
07/15/19
14:36
Earnings
Fly Intel: What to watch in next round of big banks' earnings reports »

Goldman Sachs (GS), Bank…

GS

Goldman Sachs

$211.82

-2.13 (-1.00%)

BAC

Bank of America

$29.19

-0.25 (-0.85%)

MS

Morgan Stanley

$44.60

-0.27 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 06

    Aug

  • 06

    Sep

AMBA

Ambarella

$46.20

-0.06 (-0.13%)

14:35
07/15/19
07/15
14:35
07/15/19
14:35
Options
Ambarella put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

, SPX

S&P 500

$0.00

(0.00%)

14:29
07/15/19
07/15
14:29
07/15/19
14:29
General news
Mnuchin said he thinks a budget deal is 'close' »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

, SPX

S&P 500

$0.00

(0.00%)

14:27
07/15/19
07/15
14:27
07/15/19
14:27
General news
Mnuchin says had 'very productive' talks with Pelosi on debt ceiling »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$12.55

0.41 (3.38%)

14:26
07/15/19
07/15
14:26
07/15/19
14:26
Conference/Events
LogicBio Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

QURE

uniQure

$68.66

-1.74 (-2.47%)

14:25
07/15/19
07/15
14:25
07/15/19
14:25
Options
uniQure call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

AVGO

Broadcom

$290.65

5.26 (1.84%)

, SYMC

Symantec

$21.78

-3.78 (-14.79%)

14:21
07/15/19
07/15
14:21
07/15/19
14:21
Periodicals
Broadcom still keen to find solution as Symantec bid stalls over price, FT says »

Broadcom's (AVGO)…

AVGO

Broadcom

$290.65

5.26 (1.84%)

SYMC

Symantec

$21.78

-3.78 (-14.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/15/19
07/15
14:17
07/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/15/19
07/15
14:16
07/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$26.49

-0.32 (-1.19%)

14:15
07/15/19
07/15
14:15
07/15/19
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

14:15
07/15/19
07/15
14:15
07/15/19
14:15
General news
Fed funds futures are fractionally higher »

Fed funds futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.